Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.30
Nov 13 • 3:59 PM ET Dollar change-0.05 Percentage change(-3.70%)
Aftermarket Close
1.23
Aftermarket • 7:39 PM ET Dollar change-0.07 Percentage change(-5.38%)
Index
-
Market Cap
6.47M
Enterprise Value
4.18M
Income
-8.03M
Sales
1.40M
Book/sh
3.15
Cash/sh
2.63
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
24
IPO
Jul 25, 2011
P/E
-
Forward P/E
-
PEG
-
P/S
4.62
P/B
0.41
P/C
0.49
P/FCF
-
EV/EBITDA
-
EV/Sales
2.99
Quick Ratio
1.04
Current Ratio
1.20
Debt/Eq
0.58
LT Debt/Eq
0.23
Option/Short
Yes / Yes
EPS (ttm)
-1.82
EPS next Y
-1.26
EPS next Q
-0.39
EPS this Y
-
EPS next Y
19.75%
EPS next 5Y
-
EPS past 3/5Y
75.30% 66.78%
Sales past 3/5Y
- -
EPS Y/Y TTM
55.29%
Sales Y/Y TTM
-91.94%
EPS Q/Q
31.62%
Sales Q/Q
-3.70%
Insider Own
0.56%
Insider Trans
0.00%
Inst Own
1.80%
Inst Trans
29.45%
ROA
-20.94%
ROE
-47.48%
ROIC
-47.39%
Gross Margin
55.01%
Oper. Margin
-875.98%
Profit Margin
-574.29%
SMA20
-29.55%
SMA50
-40.04%
SMA200
-51.37%
Trades
Shs Outstand
4.98M
Shs Float
4.95M
52W High
3.95 -67.09%
52W Low
1.35 -3.70%
Volatility
15.14% 8.76%
ATR (14)
0.16
RSI (14)
13.80
Beta
1.65
Rel Volume
0.81
Avg Volume
17.38K
Volume
14,111
Perf Week
-23.98%
Perf Month
-36.59%
Perf Quarter
-50.76%
Perf Half Y
-56.38%
Perf YTD
-53.07%
Perf Year
-62.54%
Perf 3Y
-97.70%
Perf 5Y
-98.85%
Perf 10Y
-99.80%
Prev Close
1.35
Price
1.30
Change %
-3.70%
Consensus
Strong Buy
Avg. Price Target
$22.00
Implied Upside
+1,592.3%
Analysts4incl. previous ratings
Rating Distribution4 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
May 18, 2017Upgrade
MMaxim Group
Hold → Buy$1 → $3+130.8%
Feb 13, 2017Initiated
RRodman & Renshaw
Buy$3+130.8%
Aug 12, 2016Downgrade
MMaxim Group
Buy → Hold$4 → $1-23.1%
Aug 17, 2015Reiterated
MMaxim Group
Buy$8 → $4+207.7%
Jul 27, 2015Reiterated
RROTH Capital
Buy$10.50 → $7+438.5%
Jun 22, 2015Initiated
JJMP Securities
Mkt Outperform$5+284.6%
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.
M.B.A.Mr. Philip A. Serlin CPA
Chief Financial OfficerMs. Mali Zeevi CPA
Chief Development OfficerDr. Ella Sorani Ph.D.
Head of Corporate Communications & Investor RelationsMr. John Lacey
Treasurer & Budgetary Control DirectorMr. Raziel Fried